Research programme: CNS disorders and substance-related disorders therapeutics - Kinoxis Therapeutics
Latest Information Update: 28 Oct 2023
At a glance
- Originator University of Sydney
- Developer Kinoxis Therapeutics
- Class Anxiolytics; Behavioural disorder therapies; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Oxytocin receptor antagonists; Oxytocin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mental disorders; Social phobia
- Research Post-traumatic stress disorders
- No development reported CNS disorders
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in CNS-disorders in Australia (PO)
- 12 Apr 2023 Early research in Post-traumatic stress disorders in Australia (PO) (Kinoxis Therapeutics pipeline, April 2023)
- 12 Apr 2023 Preclinical trials in Mental disorders in Australia (PO) (Kinoxis Therapeutics pipeline, April 2023)